Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL727443 | 0.79 | POLB (0.37) | KMT2ACYP2C19ALDH1A1TSHRLMNA | |
| SCHEMBL727450 | 0.78 | ALDH1A1 (0.35) | KMT2ACYP2C19ALDH1A1 | |
| SCHEMBL726257 | 0.76 | — | — | |
| SCHEMBL12932550 | 0.75 | — | — | |
| SCHEMBL27665877 | 0.75 | NAAA (0.40) | NAAASLC18A3KMT2ACYP2C19ALDH1A1 | |
| SCHEMBL12932504 | 0.73 | — | — | |
| SCHEMBL12932490 | 0.73 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL27929750 | 0.72 | NAAA (0.39) | NAAASLC18A3ALDH1A1 | |
| SCHEMBL12932507 | 0.71 | — | — | |
| SCHEMBL12640042 | 0.71 | ALDH1A1 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1914232-B1 | N-DIHYDROXYALKYL-SUBSTITUTED 2-OXOIMIDAZOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-20080103178-A1 | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives | MSD K.K. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1914232-A1 | N-DIHYDROXYALKYL-SUBSTITUTED 2-OXOIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-7300947-B2 | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-11-27 | — | — | US | disclosed |
| US-20070015792-A1 | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives | MSD K.K. (JP) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015792-A1 | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives | OPRL1, OPRK1, GPR119 | NAAA 791/4885SLC18A3 288/4885KMT2A 2331/4885 |
| US-20080103178-A1 | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives | OPRL1, OPRK1, GPR119 | NAAA 791/4885SLC18A3 288/4885KMT2A 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.